Inflammatory Genes in Epicardial Fat Contiguous With Coronary Atherosclerosis in the Metabolic Syndrome and Type 2 Diabetes
Open accessAbstract
OBJECTIVE: To determine changes in gene expression in epicardial adipose tissue (EAT) associated with coronary atherosclerosis (CAD) and effects of pioglitazone therapy. RESEARCH DESIGN AND METHODS: Genes were quantified by RT-PCR in EAT and thoracic subcutaneous adipose tissue (SAT) obtained during surgery in CAD patients with metabolic syndrome (MS) or type 2 diabetes and control subjects with minimal or no CAD and no MS or type 2 diabetes. RESULTS: Increased expression of interleukin-1 receptor antagonist (IL-1Ra) and IL-10, a trend for higher IL-1β, and no change in peroxisome proliferator-activated receptor-γ (PPARγ) was found in EAT from MS or type 2 diabetes. Only PPARγ mRNA was reduced in SAT. Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT. CONCLUSIONS: In MS and type 2 diabetes with CAD, proinflammatory and anti-inflammatory genes were differentially increased in EAT and selectively reduced in association with pioglitazone treatment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pioglitazone in CAD patients with T2DM or metabolic syndrome increases PPARγ in SAT and selectively reduces expression of IL-1β, IL-1Ra and IL-10 in EAT, and IL-10 in SAT, irrespective of other clinical variables.
“The treatment with pioglitazone in CAD patients with T2DM or metabolic syndrome, was shown to increase PPARγ in SAT and to selectively reduce the expression of IL-1β, IL-1Ra and IL-10 in EAT, and of IL-10 in SAT, irrespective of other clinical variables (weight, BMI, waist, fasting blood glucose, A1C, HOMA-IR, ACE inhibitors, angiotensin receptor blockers, statins, aspirin, and metformin) [120].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 16 · Cited by 121
- Authors
- Sacks, H. S., Fain, J. N., Cheema, P., Bahouth, S. W., Garrett, E., Wolf, R. Y., Wolford, D., & Samaha, J.
- Affiliations
- Baptist Memorial Hospital (US)
- University of Tennessee Health Science Center (US)
- Corresponding author
- Sacks, Harold S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-02-17
- Volume
- 34
- Issue
- 3
- Pages
- 730-733
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3041217
- OpenAlex
- W2098076446
- Cited by
- 121
- References
- 16
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 5 · 2022: 12 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 10 · 2017: 7 · 2016: 6 · 2015: 11 · 2014: 6 · 2013: 17 · 2012: 5
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- epicardial adipose tissue, coronary artery disease, metabolic syndrome, type 2 diabetes, pioglitazone, interleukin-1 receptor antagonist, IL-1β, IL-10, PPARγ, gene expression, inflammation
- MeSH terms
- Pioglitazone, Coronary Artery Disease, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Pericardium, Interleukin-10, Reverse Transcriptase Polymerase Chain Reaction, Metabolic Syndrome, Thiazolidinediones, Interleukin-1beta, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
